Oramed Pharmaceuticals Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $2M0.0% YoYTTM through 30 Jun 2026
Net Income $64.1MTTM through 30 Jun 2026
Free Cash Flow -$5.2MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
| EBITDA Margin | -726.0% |
| Operating Margin | -754.4% |
| Net Margin | 3,202.5% |
Returns
50.2%ROE
17.3%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.45x
Net Debt-$24.3Mnet cash position
Cash & Equivalents$15.2M
Quality Metrics
Altman Z-Score0.67
Piotroski F-Score2 / 9
FCF Margin-260.8%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $2M
Diluted EPS$4.13TTMFY2025: $1.51
Dividend
$0.25Per share, FY20266.30%Yield
Capital Allocation
R&D Spend$4.7M
Capex Intensity0.5%
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.